Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature

2.50
Hdl Handle:
http://hdl.handle.net/11287/593909
Title:
Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature
Authors:
Perry, Mandy ( 0000-0003-4303-2718 ) ; Bewshea, Claire; Brown, Richard; So, K.; Ahmad, Tariq; McDonald, Timothy J. ( 0000-0003-3559-6660 )
Abstract:
INTRODUCTION: The biologic anti-tumour necrosis factor alpha (anti-TNFalpha) agents infliximab and adalimumab are monoclonal antibodies with binding specificity to TNFalpha, which are used for the treatment of Crohn's disease. Clinical response is varied from complete with mucosal healing, to primary non-response, loss of response and adverse drug reactions. Measuring trough blood levels of infliximab and adalimumab may guide clinical management. The sample handling requirements for infliximab and adalimumab were previously unknown. AIM: The aim of this study was to determine the in vitro stability of infliximab and adalimumab in samples stored for up to seven days at room temperature. METHODS: Samples were stored as clotted whole blood or serum at room temperature for up to seven days, before being frozen (-20) and analysed as a batch for either infliximab or adalimumab. RESULTS: No significant difference between the concentration of infliximab and adalimumab measured in samples stored as serum or whole blood for seven days at room temperature, as compared to baseline was found (t-test; infliximab: P = .35 [serum], P = .38 [whole blood]; adalimumab: P = .12 [serum], P = .49 [whole blood]). CONCLUSION: The stability of infliximab and adalimumab at room temperature for seven days allows samples to be posted direct from clinics and research centres to the analysing laboratory.
Citation:
Ann Clin Biochem. 2015 Nov;52(Pt 6):672-4.
Publisher:
Sage
Journal:
Annals of clinical biochemistry
Issue Date:
1-Nov-2015
URI:
http://hdl.handle.net/11287/593909
DOI:
10.1177/0004563215580001
PubMed ID:
25780249
Additional Links:
http://acb.sagepub.com/cgi/pmidlookup?view=long&pmid=25780249
Type:
Journal Article
Language:
eng
ISSN:
1758-1001
Appears in Collections:
2015 RD&E publications; Exeter Clinical Laboratory International (Blood Sciences, Genetics, Cellular Pathology & Microbiology); Honorary contracts publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPerry, Mandyen
dc.contributor.authorBewshea, Claireen
dc.contributor.authorBrown, Richarden
dc.contributor.authorSo, K.en
dc.contributor.authorAhmad, Tariqen
dc.contributor.authorMcDonald, Timothy J.en
dc.date.accessioned2016-01-19T12:37:15Zen
dc.date.available2016-01-19T12:37:15Zen
dc.date.issued2015-11-01en
dc.identifier.citationAnn Clin Biochem. 2015 Nov;52(Pt 6):672-4.en
dc.identifier.issn1758-1001en
dc.identifier.pmid25780249en
dc.identifier.doi10.1177/0004563215580001en
dc.identifier.urihttp://hdl.handle.net/11287/593909en
dc.description.abstractINTRODUCTION: The biologic anti-tumour necrosis factor alpha (anti-TNFalpha) agents infliximab and adalimumab are monoclonal antibodies with binding specificity to TNFalpha, which are used for the treatment of Crohn's disease. Clinical response is varied from complete with mucosal healing, to primary non-response, loss of response and adverse drug reactions. Measuring trough blood levels of infliximab and adalimumab may guide clinical management. The sample handling requirements for infliximab and adalimumab were previously unknown. AIM: The aim of this study was to determine the in vitro stability of infliximab and adalimumab in samples stored for up to seven days at room temperature. METHODS: Samples were stored as clotted whole blood or serum at room temperature for up to seven days, before being frozen (-20) and analysed as a batch for either infliximab or adalimumab. RESULTS: No significant difference between the concentration of infliximab and adalimumab measured in samples stored as serum or whole blood for seven days at room temperature, as compared to baseline was found (t-test; infliximab: P = .35 [serum], P = .38 [whole blood]; adalimumab: P = .12 [serum], P = .49 [whole blood]). CONCLUSION: The stability of infliximab and adalimumab at room temperature for seven days allows samples to be posted direct from clinics and research centres to the analysing laboratory.en
dc.language.isoengen
dc.publisherSageen
dc.relation.urlhttp://acb.sagepub.com/cgi/pmidlookup?view=long&pmid=25780249en
dc.titleInfliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperatureen
dc.typeJournal Articleen
dc.identifier.journalAnnals of clinical biochemistryen

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.